Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-10-31T17:00:51.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.
    Difference
    0.4%
    Check dated 2026-10-24T20:05:34.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-17T20:42:19.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-10T20:51:51.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page history shows a new site revision label v3.7.0, replacing the previous v3.6.6. This indicates a system update to the page rendering and history tracking, not a change to study data or content.
    Difference
    0.1%
    Check dated 2026-09-19T22:09:21.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The history now shows a new revision entry v3.6.6, replacing the previous v3.6.5. This reflects a minor update to the page's history rather than changes to the study content.
    Difference
    0.1%
    Check dated 2026-08-29T18:53:14.000Z thumbnail image

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.